Changxin Pharma: Net Profit of RMB 132.04 Billion for the First Three Quarters of 2026, Turning a Loss into a Profit Year-on-Year. Changxin Pharma reported a net profit of RMB 132.04 billion for the first three quarters of 2026, turning a loss into a profit year-on-year. Revenue for the third quarter of 2026 was RMB 118.714 billion, a year-on-year increase of 613.18%; total revenue for the first three quarters was RMB 269.024 billion, a year-on-year increase of 738.51%. Earlier this month, it was reported that Changxin Pharma planned to repurchase company shares worth RMB 1 billion to RMB 2 billion. The repurchase price would not exceed RMB 72.69 per share, and the funds would come from its own funds or self-raised funds.